Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Min Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5664-7757; OpenAlex author ID A5100340924. Sources: OpenAlex.

Their work

Papers
39 (first author 10, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 3 papers · 2015: 4 papers · 2016: 3 papers · 2017: none · 2018: 5 papers · 2019: 3 papers · 2020: 1 paper · 2021: 4 papers · 2022: 8 papers · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 39

  1. Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3. Co-author DOI 10.1038/s41418-026-01665-1↗
  2. The multifaceted roles of deubiquitinating enzymes (DUBs) in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41419-025-08052-7↗
  3. Clinical functional proteomics of intercellular signalling in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08225-y↗
  4. A comparative study of the "superior mesenteric artery first" approach versus the conventional approach in short-term and long-term outcomes in patients with p… Co-author DOI 10.1007/s00464-023-10470-7↗
  5. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-022-01040-w↗
  6. An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1332626↗
  7. Clinical importance of preoperative red-cell volume distribution width as a prognostic marker in patients undergoing radical surgery for pancreatic cancer. First author DOI 10.1007/s00595-021-02374-7↗
  8. OPA Interacting Protein 5 Antisense RNA 1 Expedites Cell Migration and Invasion Through FOXM1/ Wnt/β-Catenin Pathway in Pancreatic Cancer. Co-author DOI 10.1007/s10620-021-06919-1↗
  9. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. First author DOI 10.1016/j.ebiom.2022.104352↗
  10. Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarcinoma: A propensity score-matching analys… Co-author DOI 10.1016/j.pan.2021.12.005↗
  11. How can we better predict the prognosis of patients with pancreatic cancer undergoing surgery using an immune-nutritional scoring system? First author DOI 10.1016/j.surg.2021.12.009↗
  12. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial. Co-author DOI 10.1136/bmjopen-2021-057128↗
  13. Aberrant RNA Splicing Is a Primary Link between Genetic Variation and Pancreatic Cancer Risk. Co-author DOI 10.1158/0008-5472.can-21-4367↗
  14. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Co-author DOI 10.1186/s13046-022-02491-2↗
  15. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.765216↗
  16. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis. First author DOI 10.3390/genes12111701↗
  17. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… Co-author DOI 10.7150/ijbs.49514↗
  18. MiR-146b-3p regulates proliferation of pancreatic cancer cells with stem cell-like properties by targeting MAP3K10. Co-author DOI 10.7150/jca.48418↗
  19. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-020-01249-8↗
  20. Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. Co-author DOI 10.1016/j.tiv.2018.10.019↗
  21. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Co-author DOI 10.1038/s41419-019-2123-y↗
  22. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. First author DOI 10.1186/s13046-019-1343-4↗
  23. Loss of Linc01060 induces pancreatic cancer progression through vinculin-mediated focal adhesion turnover. Co-author DOI 10.1016/j.canlet.2018.06.015↗
  24. Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. Co-author DOI 10.1016/j.taap.2018.08.003↗
  25. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Co-author DOI 10.18632/oncotarget.22976↗
  26. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.24443↗
  27. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells. Co-author DOI 10.7150/ijbs.26776↗
  28. Par3 regulates invasion of pancreatic cancer cells via interaction with Tiam1. First author DOI 10.1007/s10238-015-0365-2↗
  29. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Co-author DOI 10.1080/15548627.2016.1191722↗
  30. Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1144↗
  31. Expression and significance of HIF-1α and HIF-2α in pancreatic cancer. Co-author DOI 10.1007/s11596-015-1521-3↗
  32. MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. First author DOI 10.1007/s13402-014-0200-x↗
  33. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. First author DOI 10.18632/oncotarget.6298↗
  34. Upregulation of microRNA‑138‑5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. First author DOI 10.3892/mmr.2015.4031↗
  35. KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer. Co-author DOI 10.1007/s12032-014-0025-5↗
  36. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Co-author DOI 10.1007/s13277-014-2271-8↗
  37. microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Co-author PMID 25550779↗
  38. Balanced Tiam1-rac1 and RhoA drives proliferation and invasion of pancreatic cancer cells. First author DOI 10.1158/1541-7786.mcr-12-0632↗
  39. Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. Co-author DOI 10.1007/s11596-011-0481-5↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renyi Qin · 26 shared papers, 2013–2026 · strength 3.30
  2. Shutao Pan · 15 shared papers, 2018–2026 · strength 1.96
  3. Xingjun Guo · 21 shared papers, 2013–2023 · strength 1.86
  4. Taoyuan Yin · 8 shared papers, 2019–2026 · strength 1.23
  5. Ruizhi He · 13 shared papers, 2016–2022 · strength 1.11
  6. Jun Gong · 6 shared papers, 2020–2026 · strength 1.08
  7. Chunle Zhao · 8 shared papers, 2018–2026 · strength 1.03
  8. Zhenxiong Zhang · 5 shared papers, 2022–2026 · strength 0.89
  9. Li Xu · 9 shared papers, 2013–2022 · strength 0.88
  10. Min Zhou · 4 shared papers, 2023–2026 · strength 0.86
  11. Xiuhui Shi · 8 shared papers, 2018–2022 · strength 0.75
  12. Jianxin Jiang · 13 shared papers, 2013–2020 · strength 0.72
  13. Yan Zhao · 8 shared papers, 2016–2022 · strength 0.60
  14. Yongkang Shi · 3 shared papers, 2022–2026 · strength 0.55
  15. Min Zhou · 5 shared papers, 2018–2022 · strength 0.54
  16. Chengjian Shi · 6 shared papers, 2016–2022 · strength 0.50
  17. Renyi Qin · 4 shared papers, 2016–2022 · strength 0.48
  18. Xu Li · 7 shared papers, 2011–2022 · strength 0.47
  19. Min Zhou · 5 shared papers, 2018–2021 · strength 0.47
  20. Chao Dang · 2 shared papers, 2022 · strength 0.45
  21. Yuhui Liu · 4 shared papers, 2019–2022 · strength 0.41
  22. Guangbing Xiong · 2 shared papers, 2021–2025 · strength 0.41
  23. Shuo Yu · 3 shared papers, 2018–2021 · strength 0.33
  24. Yu Bai · 1 shared paper, 2026 · strength 0.26
  25. Chao Yu · 5 shared papers, 2014–2015 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.